Brief: Inhibikase Therapeutics Announces Dosing Of First Parkinson's Patient In Its Phase 1B Clinical Trial Of IkT-148009
19/10/2021 13:08
Oct 19 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS ANNOUNCES DOSING OF FIRST
PARKINSON'S
PATIENT IN ITS PHASE 1B CLINICAL TRIAL OF IKT-148009
* INHIBIKASE THERAPEUTICS - ANTICIPATE COMPLETING STUDY AND
ADVANCING INTO PHASE 2A STUDY IN 2022
Source text for Eikon: ID:nPncfNMR5a
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary